RESP

Expected Value of Sample Information Calculations for Risk Prediction Model Validation

Med Decis Making. 2025 Apr;45(3):232-244. doi: 10.1177/0272989X251314010. Epub 2025 Feb 18. PMID: 39963746; PMCID

Developing an online infrastructure to enhance model accessibility and validation: The Peer Models Network

Pharmacoeconomics. 2022 Oct;40(10):1005-1009. doi: 10.1007/s40273-022-01179-x.

Identification of distributions for risks based on the first moment and c-statistic

ArXiv. 2024 Sep 13. arXiv:2409.09178. Preprint.

Evaluating Treatment Benefit Predictors using Observational Data: Contending with Identification and Confounding Bias

ArXiv. 2024 Jul 8. arXiv:2407.05585. Preprint.

Expected value of sample information calculations for risk prediction model development

ArXiv. 2024 Oct 4. arXiv:2410.03096. Preprint.

Model-Based ROC Curve: Examining the Effect of Case Mix and Model Calibration on the ROC Plot

Medical Decision Making. October 2021. doi:10.1177/0272989X211050909

Marginal versus conditional odds ratios when updating risk prediction models

Epidemiology. 2022 Jul 1;33(4):555-558. doi: 10.1097/EDE.0000000000001489.

Value-of-Information Analysis for External Validation of Risk Prediction Models

Med Decis Making. 2023 Jul;43(5):564-575. doi: 10.1177/0272989X231178317.

Methodological concerns about "concordance-statistic for benefit" as a measure of discrimination in predicting treatment benefit

Diagn Progn Res. 2023 May 16;7(1):10. doi: 10.1186/s41512-023-00147-z

Non-parametric inference on calibration of predicted risks

Stat Med. 2024 Jun 11. doi: 10.1002/sim.10138.

Closed-Form Solution of the Unit Normal Loss Integral in Two-Dimensions

Med Decis Making. 2023 Jul;43(5):621-626

A parametric model to jointly characterize rate, duration, and severity of exacerbations in episodic diseases

A parametric model to jointly characterize rate, duration, and severity of exacerbations in episodic diseases. BMC Med Inform Decis Mak. 2023 Jan 12;23(1):6. doi: 10.1186/s12911-022-02080-5

A parametric model to jointly characterize rate, duration, and severity of exacerbations in episodic diseases. BMC Med Inform De...

A Threshold-Free Summary Index for Quantifying the Capacity of Covariates to Yield Efficient Treatment Rules

Statistic in Medicine. 2020;10.1002/sim.8481

The association between rate and severity of exacerbations in chronic obstructive pulmonary disease: an application of a joint frailty-logistic model

Am J Epidemiol. 2016;184(9):681–689

Relative Impact Characteristic (RIC) curve: a graphical tool to visualize and quantify the clinical utility and population-level consequences of implementing markers

Ann Epidemiol. 2018 Oct;28(10):717-723.e3

Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcome

Pharmacoeconomics. 2014 Oct;32(10):995-1004

A statistical method was used for the meta-analysis of tests for latent TB in the absence of a gold standard, combining random-effect and latent-class methods to estimate test accuracy

J Clin Epidemiol. 2010 Mar;63(3):257-69

Incorporating external evidence in trial-based cost-effectiveness analysis: the use of resampling methods

Trials. 2014 Jun 3;15:201

The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis – a case study of pharmacotherapies for moderate to severe COPD

Cost Eff Resour Alloc. 2014 Mar 13;12(1):8

Two-level resampling as a novel method for calculation of the expected value of sample information in economic trials

Health Econ. 2013 Jul;22(7):877-82

Heterogeneity’s ruses: the neglected role of between-individual variability in longitudinal studies of COPD exacerbations

Thorax. 2014 Nov;69(11):1043-4

Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information

Value Health. 2013;16(2):438–448

Predicting severe COPD exacerbations: A population surveillance approach with administrative data

Under review

Lowering the P Value Threshold

Lowering the #pvalue threshold for phase 3 RCTs is inappropriate, as high prior probability of replication (68%) leads to high positive predictive values (97%) when p=0.05

Lowering the #pvalue threshold for phase 3 RCTs is inappropriate, as high prior probability of replication (68%) leads to high p...

The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology.

Using robust statistical methodology that controlled for heterogeneity in exacerbation rates among individuals, we demonstrated potential causal associations among past and future severe exacerbations, albeit the magnitude of association was noticeably low...

Using robust statistical methodology that controlled for heterogeneity in exacerbation rates among individuals, we demonstrated...

The “Lost NNT” can be used to represent uncertainty surrounding number needed to treat

Currently, confidence interval is the standard way of communicating uncertainty around the number needed to treat (NNT). But the CI is not directly relevant to the treatment decision.Uncertainty around treatment only matters because it may result in the ch...

Currently, confidence interval is the standard way of communicating uncertainty around the number needed to treat (NNT). But the...

Faculty of Pharmaceutical Sciences & UBC Division of Respiratory Medicine Respiratory Evaluation Sciences Program

Faculty of Pharmaceutical Sciences & UBC Division of Respiratory Medicine
Respiratory Evaluation Sciences Program